AI assistant
DEXCOM INC — Director's Dealing 2016
Sep 13, 2016
30198_dirs_2016-09-13_fc8140b4-ad23-4171-ad12-2091e4af474c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2016-09-09
Reporting Person: DOUBLEDAY RICHARD (EVP, Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-09-09 | Common Stock | D | 4445.0 | $93.7227 | Disposed | 87805 | Direct |
| 2016-09-09 | Common Stock | D | 4223.0 | $93.7227 | Disposed | 83582 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 31825 | Indirect |
Footnotes
F1: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.
F2: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018, and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017.
F3: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.